Roche's dual GLP-1/GIP results show promising weight loss, but also high rates of vomiting
Roche’s new weight loss candidate has the efficacy the Swiss pharma was looking for. But it also comes with a high rate of side effects …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
